Toripalimab injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Brand

Tuoyi / Loqtorzi

Medicine type

Biologic

Therapeutic area

Oncology

Indications recorded in the public source

1. Unresectable or metastatic melanoma after failure of prior systemic therapy. 2. First-line treatment of unresectable or metastatic melanoma. 3. Locally advanced or metastatic urothelial carcinoma after failure of platinum-containing chemotherapy, including progression within 12 months of neoadjuvant or adjuvant chemotherapy. 4. Recurrent or metastatic nasopharyngeal carcinoma after failure of at least two lines of systemic therapy. 5. With cisplatin and gemcitabine for first-line treatment of locally recurrent or metastatic nasopharyngeal carcinoma. 6. With paclitaxel and cisplatin for first-line treatment of unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma. 7. With pemetrexed and a platinum agent for first-line treatment of unresectable locally advanced or metastatic nonsquamous NSCLC without EGFR mutations or ALK alterations. 8. With platinum-containing chemotherapy as perioperative treatment, followed by toripalimab monotherapy as adjuvant treatment, for adults with resectable stage IIIA-IIIB NSCLC. 9. With axitinib for first-line treatment of intermediate- or high-risk unresectable or metastatic renal cell carcinoma. 10. With etoposide and a platinum agent for first-line treatment of extensive-stage SCLC. 11. With albumin-bound paclitaxel for first-line treatment of recurrent or metastatic triple-negative breast cancer that is PD-L1 positive (CPS >=1) by an adequately validated test. 12. With bevacizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma. Added in China in May 2026: With disitamab vedotin for first-line treatment of HER2-expressing (IHC 1+, 2+ or 3+) locally advanced or metastatic urothelial carcinoma.

Indication source and scope

Source date(s): 2025, 2026, 2026-05-21. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.

Prescribing-information limitations

Complete official prescribing information obtained. The available full label is from an overseas jurisdiction; a complete current Chinese label remains unavailable. Chinese indications are supported separately by Chinese sources.

China availability status

Historical Chinese approval verified; current continuous market availability has not been checked for every product.

Overseas status

Canada: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.

Insurance classification

Included in national insurance (Category B)

Insurance edition

2025 edition; effective 1 January 2026

Insurance restrictions

Limited to: 1. Unresectable or metastatic melanoma after failure of prior systemic therapy. 2. First-line treatment of unresectable or metastatic melanoma. 3. Locally advanced or metastatic urothelial carcinoma after failure of platinum-containing chemotherapy, including progression within 12 months of neoadjuvant or adjuvant chemotherapy. 4. Recurrent or metastatic nasopharyngeal carcinoma after failure of at least two lines of systemic therapy. 5. With cisplatin and gemcitabine for first-line treatment of locally recurrent or metastatic nasopharyngeal carcinoma. 6. With paclitaxel and cisplatin for first-line treatment of unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma. 7. With pemetrexed and a platinum agent for first-line treatment of unresectable locally advanced or metastatic nonsquamous NSCLC without EGFR mutations or ALK alterations. 8. With platinum-containing chemotherapy as perioperative treatment, followed by toripalimab monotherapy as adjuvant treatment, for adults with resectable stage IIIA-IIIB NSCLC. 9. With axitinib for first-line treatment of intermediate- or high-risk unresectable or metastatic renal cell carcinoma. 10. With etoposide and a platinum agent for first-line treatment of extensive-stage SCLC. 11. With albumin-bound paclitaxel for first-line treatment of recurrent or metastatic triple-negative breast cancer that is PD-L1 positive (CPS >=1) by an adequately validated test. 12. With bevacizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma.

Insurance period

2026-01-01 to 2027-12-31

Insurance verification notes

Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

• https://m.cnpharm.com/c/2019-07-01/497890.shtml
• https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
• https://www.nhsa.gov.cn/attach/Ypsn2025/YPSN202500190/YPSN202500190.pdf
• https://www.junshipharma.com/%E5%90%9B%E5%AE%9E%E7%94%9F%E7%89%A9%E5%AE%A3%E5%B8%83%E7%89%B9%E7%91%9E%E6%99%AE%E5%88%A9%E5%8D%95%E6%8A%97%E4%B8%80%E7%BA%BF%E6%B2%BB%E7%96%97her2%E8%A1%A8%E8%BE%BE%E5%B0%BF%E8%B7%AF%E4%B8%8A-2/

Open the interactive record, public price references and discussions